Overview

Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer

Status:
Not yet recruiting
Trial end date:
2026-10-01
Target enrollment:
0
Participant gender:
All
Summary
To explore the efficacy and safety of Fruquintinib combined with Sintilimab and XELOX in the first-line treatment of unresectable advanced metastatic gastric or gastroesophageal junction adenocarcinoma.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Second Affiliated Hospital of Nanchang University
Treatments:
Capecitabine
Oxaliplatin
Criteria
Inclusion Criteria:

1. Have fully understood the study and voluntarily signed the informed consent;

2. Histologically and/or cytologically confirmed unresectable advanced gastric or
gastroesophageal junction adenocarcinoma;

3. Age 18-75 (including 18 and 75 years old);

4. ECOG physical condition 0-1 score;

5. Locally advanced unresectable or metastatic gastric/gastroesophageal junction
adenocarcinoma that has not received systemic therapy before (Note: Time from the end
of previous (new) adjuvant chemotherapy/adjuvant radiotherapy to disease recurrence
> 6 months);

6. For local lesions (non-target lesions), the time from the end of palliative treatment
to random enrollment was > 2 weeks;

7. At least one measurable or evaluable lesion according to RECIST v1.1 criteria;

8. Negative Her2;

9. Expected survival ≥3 months;

10. The functions of vital organs during the first 14 days of enrollment met the following
requirements:

- Absolute neutrophil count ≥1.5×109/L;

- Platelet ≥80×109/L;

- Hemoglobin ≥90g/L;

- Total bilirubin < 1.5 ULN;

- ALT and AST < 2.5 ULN (< 5 ULN in patients with liver metastasis);

- Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance (CCr)≥60ml/min;

- endogenous creatinine clearance > 50ml/min;

11. Female subjects of childbearing age or male subjects whose sexual partner is a female
of childbearing age should take effective contraceptive measures throughout the
treatment period and 6 months after the treatment period;

12. Good compliance, cooperate with follow-up.

Exclusion Criteria:

1. Failure to comply with the study protocol or study procedure;

2. Previous treatment with vascular endothelial growth factor receptor (VEGFR) inhibitors
or previous treatment with immune checkpoint inhibitors;

3. Have had other malignancies within the past 5 years, except basal cell or squamous
cell carcinoma of the skin after radical surgery, or carcinoma in situ of the cervix;

4. Known presence of symptomatic central nervous system metastasis and/or cancerous
meningitis. Participants with previously treated BMS may participate in the trial if
their condition is stable (no evidence of radiographic progression at least 4 weeks
prior to initial administration of the trial treatment), repeated radiographic studies
confirm no evidence of new BMS or enlargement of the original BMS, and no steroid
therapy is required at least 14 days prior to initial administration of the trial
treatment. This exception does not include cancerous meningitis, which should be
excluded regardless of whether it is clinically stable;

5. Had autoimmune disease or history of autoimmune disease within 4 weeks before
enrollment;

6. Previously received allogeneic bone marrow transplantation or organ transplantation;

7. Uncontrolled malignant ascites (defined as ascites that cannot be controlled by
diuretics or puncture as determined by the researcher);

8. Severe cardiovascular disease, including unstable angina pectoris or myocardial
infarction, occurs within 6 months before the start of study treatment;

9. Subjects who are allergic to the investigational drug or any of its adjuncts;

10. Participated in other domestic unapproved or unmarketed drug clinical trials and
accepted the corresponding experimental drug treatment within 4 weeks before
enrollment;

11. Had a major surgical procedure (craniotomy, thoracotomy, or laparotomy) within 4 weeks
prior to the first dose of study therapy or expected to require major surgery during
study therapy.

12. International Standardized Ratio (INR) > 1.5 or partially activated prothrombin
time (APTT) > 1.5×ULN;

13. The investigator identified clinically significant electrolyte abnormalities;

14. Hypertension that could not be controlled by drugs before enrollment was defined as:
systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg;

15. Poorly controlled diabetes mellitus was present before enrollment (fasting glucose
concentration ≥CTCAE level 2 after formal treatment);

16. Had any disease or condition prior to enrollment that affected drug absorption, or the
patient could not take fuquintinib orally;

17. Gastrointestinal diseases such as active ulcer of stomach and duodenum, ulcerative
colitis, or active bleeding of unresectosed tumors, or other conditions that may cause
gastrointestinal bleeding or perforation as determined by researchers before
enrollment;

18. Patients with evidence or history of significant bleeding tendency within 3 months
prior to enrollment (bleeding within 3 months > 30 mL, hematemesis, stool, stool
blood), hemoptysis (within 4 weeks > 5 mL of fresh blood) or had a thromboembolic
event (including stroke events and/or transient ischemic attacks) within 12 months;

19. Hepatic encephalopathy, hepatorenal syndrome or Child-Pugh grade B or more severe
cirrhosis;

20. A history of intestinal obstruction or the following diseases: inflammatory bowel
disease or extensive enterectomy (partial resection of the colon or extensive
resection of the small intestine with chronic diarrhea), Crohn's disease, ulcerative
colitis;

21. Clinically significant cardiovascular disease, including but not limited to acute
myocardial infarction, severe/unstable angina pectoris, or coronary artery bypass
grafting within 6 months prior to enrollment; New York Heart Association (NYHA) Grades
for Congestive Heart Failure > Level 2; Ventricular arrhythmias requiring medical
treatment; LVEF (Left ventricular Ejection Fraction) < 50%;

22. Active or uncontrolled severe infection (≥CTCAE v5.0 grade 2 infection);

23. Known human immunodeficiency virus (HIV) infection. Known history of clinically
significant liver disease, including viral hepatitis [Known hepatitis B virus (HBV)
carriers must rule out active HBV infection, i.e., positive HBV DNA (>1×104 copies
/mL or > 2000 IU/ml); known hepatitis C virus infection (HCV) and HCV RNA positive
(>1×103 copies /mL)];

24. Unmitigated toxicity higher than CTCAE v5.0 grade 1 due to any previous anticancer
therapy, excluding alopecia, lymphocytopenia, and oxaliplatin grade ≤2 neurotoxicity;

25. Women who are pregnant (positive pregnancy test before medication) or breastfeeding;

26. Received blood transfusion therapy, blood products and hematopoietic factors, such as
albumin and granulocyte colony-stimulating factor (G-CSF), within 14 days before
enrollment;

27. Urine routine indicated urinary protein ≥2+, and 24-hour urinary protein volume >
1.0g;

28. Complications require long-term treatment with immunosuppressants or systemic or local
use of immunosuppressive corticosteroids (> 10mg/ day prednisone or other
therapeutic hormone);

29. Any other medical condition, clinically significant metabolic abnormality, physical
abnormality or laboratory abnormality, which, in the investigator's judgment,
reasonably suspects that the patient has a medical condition or condition that is not
suitable for the use of the investigational drug (such as having seizures and
requiring treatment), or which would affect the interpretation of the study results or
place the patient at high risk。